Experimental Autoimmune Encephalomyelitis Ameliorated by Passive Transfer of Polymerase 1-Silenced MOG35-55 Lymphatic Node Cells: Verification of a Novel Therapeutic Approach in Multiple Sclerosis
- 28 July 2017
- journal article
- research article
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 19 (2-3) , 406-412
Abstract
In the current study, we present an innovative concept based on the knowledge that enhancing naturally occurring biological mechanisms is effective in preventing neuronal damage and maintaining low disease activity in about 15% of multiple sclerosis (MS) patients presenting the benign type of MS. Recently, we have demonstrated that low disease activity in benign MS is associated with suppression of RNA polymerase 1 (POL1) pathway; therefore, targeting POL1 transcription machinery as a strategy for suppressing active forms of MS is suggested. To further establish our approach, we aimed to suppress POL1 pathway by silencing of the POL1-related RRN3, POLR1D and LRPPRC genes in specific MOG35-55-activated lymphocytes and assess their capacity to induce experimental autoimmune encephalomyelitis (EAE) by passive transfer. We have demonstrated that silencing of specific POL1 pathway-related genes significantly decreased viability and increased the proportion of CD4+/AnnexinV+/PI+ apoptotic cells in MOG35-55-primed lymphocytes. POL1-gene silencing significantly decreased the proportion of CD4+IL17+ and increased proportion of CD4+IL10+ and CD4+TNFa+ lymphocytes that occurred simultaneously with over-presentation of Treg CD4+CD25+FoxP3+ cells. Passive transfer of MOG35-55-primed lymphocytes after POL1-gene silencing suppressed EAE development in mice as demonstrated by delayed onset and peak of disease accompanied by significantly lower maximal and cumulative EAE scores. Our study supports a basis for direct targeting of POL1 transcription pathway as a strategy for selective induction of apoptosis and suppression of inflammation in EAE and consequently paves the way for innovative and targeted MS therapeutic strategy that is based on naturally existing biological mechanism.Keywords
Funding Information
- National Network of Excellence in Neuroscience – Israel ((NNE) - 2014
This publication has 18 references indexed in Scilit:
- DNA Binding by the Ribosomal DNA Transcription Factor Rrn3 Is Essential for Ribosomal DNA TranscriptionJournal of Biological Chemistry, 2013
- Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple SclerosisPLOS ONE, 2012
- Pathogenic and Protective Functions of TNF in Neuroinflammation Are Defined by Its Expression in T Lymphocytes and Myeloid CellsThe Journal of Immunology, 2011
- The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cellsOncogene, 2011
- Long-term follow-up of benign multiple sclerosis in Hordaland County, Western NorwayMultiple Sclerosis Journal, 2009
- Multiple sclerosisThe Lancet, 2008
- Predictive value of clinical characteristics for ‘benign’ multiple sclerosisEuropean Journal of Neurology, 2007
- Genetic Inactivation of the Transcription Factor TIF-IA Leads to Nucleolar Disruption, Cell Cycle Arrest, and p53-Mediated ApoptosisMolecular Cell, 2005
- Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curvesJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factorsJournal of Neurology, Neurosurgery & Psychiatry, 1999